Navigation Links
Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
Date:3/18/2009

disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes are described in greater detail in the reports Nile files with Securities and Exchange Commission, including the "Risk Factors" section in Item 1A of the Form 10-K Nile filed with the Securities and Exchange Commission on March 12, 2009. Nile is providing this information as of the date of this press release and does not undertake any obliga
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at the Needham Cancer Therapeutics Conference
2. Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is seeking ... stem cells for dogs with osteoarthritis. Dr. McCarthy has ... clinical stem cell therapy for 7 years. The ultimate ... single injection of donor stem cells into one or ... inflammation in the treated joints. , Candidates for ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... venture capital in more deals in 2006, but the improvement ... Ernst & Young, LLP and Dow Jones ... in 2006, including a $12 .5 million round by ... for a total of $58.47 million. The total, up from ...
... Lance Armstrong is a unique phenomenon. He's a talented athlete, ... league by himself. Or is he? , ,As many people know, ... National Center for Health Statistics report released by the ... the second year in a row. , ,Cancer patients as political ...
... director of technology programs for the University of Wisconsin-Madison, is ... he demonstrates in Part II of this interview. In ... In Part II (below), he addresses creating a culture of ... also is a featured speaker at the Fusion 2007 ...
Cached Biology Technology:Wisconsin fares slightly better in venture capital chase 2Wisconsin fares slightly better in venture capital chase 3Lance Armstrong and the future of cancer care 2Lance Armstrong and the future of cancer care 3Lance Armstrong and the future of cancer care 4Lance Armstrong and the future of cancer care 5
(Date:10/14/2014)... JOLLA, CA – October 14, 2014 – Scientists from ... million from the National Institutes of Health (NIH) to ... prevalent virus-induced hemorrhagic fever disease in Africa. The study ... and why some patients die, while others survive the ... to understand the basic mechanism of how Lassa fever ...
(Date:10/14/2014)... team of researchers, led by the Chinese Academy of ... Nature Genetics a brief genomic history of tomato ... tomato plant. , The C.M. Rick Tomato Genetics Resource ... this study by providing seed of both cultivated tomato ... builds on the first tomato genome sequence completed just ...
(Date:10/14/2014)... October 14, 2014 – Over the past decades, we ... institutions to meet the needs of infants for social ... these infants to thrive. , Infancy and ... of the cortex. A generation of research suggests that ... cortical development and cognitive function. In contrast, deprivation and ...
Breaking Biology News(10 mins):Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2Institutional rearing may increase risk attention-deficit disorder 2
... that links global warming to the recent extinction of ... evidence of a large phenomena that may affect broad ... researchers at Oregon State University. , A study being ... that global climate change created favorable conditions for a ...
... Assertive and even aggressive human behavior could explain why ... downward trend in close encounters with the oceanic predators, ... precautions and in-your-face responses to confrontations with sharks went ... attacks from 65 in 2004 to 58 in 2005 ...
... Very thin but hardy, unblemished skin and slow developing ... hatched Antarctic notothenioids, a group of fish whose adults ... in their blood. , Such adaptations are important, researchers ... larval fish of at least two species of notothenioids ...
Cached Biology News:Extinctions linked to climate change 2Extinctions linked to climate change 3World shark attacks dipped in 2005, part of long-term trend 2World shark attacks dipped in 2005, part of long-term trend 3Thin tough skin, slow-growing gills protect larval Antarctic fish 2Thin tough skin, slow-growing gills protect larval Antarctic fish 3
... demands of the routine trace metal analytical ... robust and simple to use instrumentation. The ... most challenging sample matrices found in the ... the toughest analytical challenges found in the ...
... Do you need to make your strain ... efficiency? Take advantage of Lucigen’s unrivalled expertise ... Competent Cell Service offers: Chemically ... efficiencies Fast turnaround ...
Procollagen type I C-terminal propeptide (human, PICP)...
... in Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, ... Germany) have collaborated to develop a fluorescence ... The DNAscope AT is based on ... AT automatically reads up to six ArrayTubes ...
Biology Products: